Related Experiment Video

Updated: Aug 1, 2025

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

3.7K

Generation of a genetically-modified induced pluripotent stem cell line harboring an oncogenic gene variant KRAS

Alexandra Viktoria Busley1, Mandy Kleinsorge2, Lukas Cyganek1

  • 1Stem Cell Unit, Clinic for Cardiology and Pneumology, University Medical Center Göttingen, Göttingen, Germany; DZHK (German Center for Cardiovascular Research), Partner Site Göttingen, Germany; Cluster of Excellence "Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells" (MBExC), University of Göttingen, Germany & Hertha Sponer College, Göttingen, Germany.

Stem Cell Research
|April 30, 2023
PubMed

Insights

Researchers created a human induced pluripotent stem cell (iPSC) line with the KRAS G12V mutation. This KRAS G12V iPSC line aids in studying cancer signaling pathways and developing new cancer drugs.

Area of Science:

  • Molecular Biology
  • Genetics
  • Stem Cell Biology

Background:

  • Activating KRAS codon 12 variants cause RAS-MAPK and PI3K-AKT pathway hyperactivity.
  • These variants are implicated in the development of various carcinomas.

Purpose of the Study:

  • To generate a human induced pluripotent stem cell (iPSC) line harboring the KRAS p.G12V variant.
  • To establish a platform for studying oncogenic KRAS-induced signaling and its physiological impact.
  • To enable drug and toxicity screenings for novel chemotherapeutic agents.

Main Methods:

  • CRISPR/Cas9 gene editing technology was employed.
  • Generation of a human iPSC line with the specific KRAS G12V mutation.

Main Results:

  • Successfully established a human iPSC line carrying the KRAS G12V oncogenic variant.
  • The iPSC line facilitates investigation of oncogenic KRAS-driven signaling.
  • The cell line provides a model for studying effects on iPSC-derived cell types and tissues.

Conclusions:

  • The KRAS G12V iPSC line is a valuable tool for understanding oncogenic KRAS.
  • This platform supports the identification of new chemotherapeutic drugs through screening.
  • Enables research into cancer signaling and potential therapeutic interventions.

More Related Videos

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System05:45

In Vitro Establishment of a Genetically Engineered Murine Head and Neck Cancer Cell Line using an Adeno-Associated Virus-Cas9 System

Published on: January 9, 2020

8.0K
Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets07:08

Author Spotlight: Reprogramming Cancer Cells to iPSCs to Study Disease Progression and Treatment Targets

Published on: February 2, 2024

870

Related Concept Videos

Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.2K
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.3K